
Opinion|Videos|May 7, 2024
Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD
Turning the focus to non-statin therapies, the panel outlines logistical barriers and discusses the characteristics that guide treatment selection in patients with ASCVD.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
3
Workforce Preparation for Fall Immunization Season Starts Now
4
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
5







































































































